A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - A staphylokinase variant. I. In vitro study

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 10, 2005, Pages 2156-2165

  Walkowiak, B ^b,c   Kawecka, I ^a   Janiszewska, G ^a   Buczko, W ^a   Bartkowiak, J ^a   Chabielska, E ^d   Szemraj, Janusz ^a,b  

^a Department of Medical Biochemistry ^*  (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

^d MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Antiplatelet activity; Hirudin and K2 domain of t PA; Recombinant protein; Staphylokinase; Thrombolysis; Thrombolytic and antithrombotic agents

Indexed keywords

ANTICOAGULANT AGENT; ARGINYLGLYCYLASPARTIC ACID; COMPLEMENTARY DNA; FIBRIN; FIBRINOLYTIC AGENT; HIRUDIN; HYBRID PROTEIN; RECOMBINANT PROTEIN; STAPHYLOKINASE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG ACTIVITY; FIBRINOLYSIS; IN VITRO STUDY; KRINGLE DOMAIN; MOLECULAR CLONING; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; THROMBOCYTE AGGREGATION;

CLONING, MOLECULAR; DRUG DESIGN; FIBRIN; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HIRUDINS; HUMANS; KINETICS; METALLOENDOPEPTIDASES; OLIGOPEPTIDES; PLATELET AGGREGATION; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; THROMBIN; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 28444451127     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01480.x     Document Type: Article

References (27)

1. Collen D, Lijnen HR. Molecular basis of thrombolytic therapy. J Nucl Cardiol 2000; 7: 373-81.
2. Armstrong PW, Burton J, Pakola S, Molhock PG, Betriu A, Tendera M, Bode C, Adgey A, Bar F, Vahanian A, Van der Werf F. Collaborative angiographic patency trial of recombinant staphylokinase (Captors II). Am Heart J 2003; 146: 484-8.
3. Moreadith RW, Collen D. Clinical development of PEGylated recombinant staphylokinase (PEG-SAK) for bolus thrombolytic treatment of patients with acute myocardial infraction. Adv Drug Deliv Rev 2003; 55: 1335-45.
4. Szarka SJ, Sihota EG, Habibi HR, Wong SL. Staphylokinase as a plasminogen activator component in recombinant fusion proteins. Appl Environ Microbiol 1999; 65: 506-13.
5. van Zyl WB, Pretorius GH, Lamprecht S, Roodt JP, Kotze HF. Antithrombotic and fibrinolytic protein, inhibits arterial and venous thrombosis in baboon model. Thromb Res 2000; 98: 435-43.
6. Lian Q, Szarka SJ, Ng KS, Wond S-L. Engineering of staphylokinase-based fibrinolytic agent with antithrombotic activity and targeting capability towards thrombin-rich fibrin and plasma clots. J Biol Chem 2003; 278: 26677-86.
7. Wu S-C, Castellino FJ, Wong S-L. A fast-acting, modular structured staphylokinase fusion with kringle 1 from human plasminogen as the fibrin targeting domain offers improved clot-lysis efficacy. J Biol Chem 2003; 278: 18199-206.
8. Icke Ch, Schlott B, Ohlenschlager OM, Guhrs K, Glusa E. Fusion proteins with anticoagulant and fibrinolytic properties: functional studies and structural considerations. Mol Pharmacol 2002; 62: 203-9.
9. Deutsch DG, Metz ET. Plasminogen purification from human plasma by affinity chromatography. Science 1970; 170: 1095-6.
10. Lijnen HR, Van Hoef B, Collen D. Comparative kinetic analysis of the activation of human plasminogen natural and recombinant single-chain urokinase-type activator. Biochem Biophys Acta 1986; 884: 402-8.
11. Collen D, De Cock F, Demarsin E, Jenne S. Recombinant staphylokinase variants with altered immunoreactivity. III: Species variability of antibody binding patterns. Circulation 1997; 95: 455-62.
12. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid uranidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 196: 156-9.
13. Rodriques P, Hernandez L, Munoz E, Castro A, De la Fuente J, Herrera L. Purification of streptokinase by affinity chromatography on immobilized acylated human plasminogen. Biotechnics 1999; 12: 424-9.
14. Miele R, Prorok M, Costa A, Castellino FJ. Glycosylation of asparagine-28 of recombinant staphylokinase with high-mannose-type oligosaccharides results in a protein with highly attenuated plasminogen activator activity. J Biol Chem 1999; 274: 7769-76.
15. Vanwetswinkel S, Plaisance S, Zhi-Young Z, Vanlinthout I, Brepoels K, Lasters I, Collen D, Jespers L. Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase. Blood 2000; 95: 936-42.
16. Matsuo O, Okada K, Fukao H, Tomioka Y, Ueshima S, Watanuki M, Sakai M. Thrombolytic properties of staphylokinase. Blood 1990; 76: 925-9.
17. Riesbeck K, Chen D, Kemball-Cook G, Mc Vey JH, George AJT, Tuddenham E, Dorling A, Lechler R. Expression of hirudin fusion proteins in mammalian cells. A strategy for prevention of intravascular thrombosis. Circulation 1998; 98: 2744-52.
18. Mustard JF, Perry DW, Ardlie NC, Pachman MA. Preparation of suspensions of washed platelets from humans. Br J Haematol 1977; 22: 193-204.
19. Walkowiak B, Kralisz U, Michalec L, Majewska E, Koziokiewicz W, Ligocka A, Cierniewski C. Comparison of platelet aggregability and P-selectin surface expression on platelets isolated by different methods. Thromb Res 2000; 99: 495-502.
20. Walkowiak B, Michalak E, Koziolkiewicz W, Cierniewski C. Rapid photometric metod for estimation of platelet count in blood plasma or platelet suspension. Thromb Res 1989; 56: 763-6.
21. Collen D, Bernaerts R, Declerck P. Recombinant staphylokinase variants with altered immunoreactivity. I. Construction and characterization. Circulation 1996; 94: 197-206.
22. Ruoslahti E, Pierschoacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238: 491-7.
23. 2-antiplasmin-deficient mice. Blood Coagul Fibrinol 2000; 11: 645-55.
24. Bakker A, van der Greef W, Rehberg E, Marotti K, Verheijen J. Introduction of lysine and clot binding properties in the kringle one domain of tissue-type plasminogen activator. J Biol Chem 1993; 268: 18496-501.
25. Horrevoets A, Smilde A, de Vries C, Pannekoek H. The specific roles of finger and kringle 2 domains of tissue-type plasminogen activator during in vitro fibrinolysis. J Biol Chem 1994; 269: 12639-44.
26. Kim D, Horbett TA, Takeno M, Ratner D. Pharmacology and controlled release of hirudin for cardiovascular disorders. Cardiovasc Pathol 1996; 5: 337-349.
27. Ruoslahti E. RGD other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996; 12: 697-715.